BLCO vs HSIC vs ATRC

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus 4. 0% for Henry Schein, Inc. (HSIC). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate AtriCure, Inc. (ATRC) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Henry Schein, Inc.

is actually cheaper at 13. 2x.

Over the past 5 years, Henry Schein, Inc.

(HSIC) delivered a total return of -14. 6%, compared to -64. 2% for AtriCure, Inc. (ATRC). Over 10 years, the gap is even starker: ATRC returned +84. 4% versus BLCO's -19. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Henry Schein, Inc.

(HSIC) is the lower-risk stock at 0. 72β versus Bausch + Lomb Corporation's 1. 36β — meaning BLCO is approximately 88% more volatile than HSIC relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 82% for Bausch + Lomb Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus 4. 0% for Henry Schein, Inc. (HSIC). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -13. 3% for Bausch + Lomb Corporation. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Henry Schein, Inc.

(HSIC) is the more profitable company, earning 3. 0% net margin versus -7. 1% for Bausch + Lomb Corporation — meaning it keeps 3. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HSIC leads at 5. 7% versus -0. 6% for ATRC. At the gross margin level — before operating expenses — ATRC leads at 74. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Henry Schein, Inc.

(HSIC) trades at 13. 2x forward P/E versus 428. 7x for AtriCure, Inc. — 415. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 95. 3% to $51. 33.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Henry Schein, Inc.

(HSIC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 72)). Both have compounded well over 10 years (HSIC: +5. 8%, BLCO: -19. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.